Evidence map›Paper›PMID 42316222›Full record

ArticleJournal of biological engineering2026

Engineering of Corynebacterium glutamicum for biosynthesis of the pharmaceutically active N-acetyltyramine: establishing and optimizing de novo production.

Sara-Sophie Poethe, Lilli Sophie Kaimann, Kai H Schülke, Stephan C Hammer, Volker F Wendisch

Abstract read
In one paragraph

Article in Journal of biological engineering, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Sara-Sophie PoetheGenetics of Prokaryotes, Faculty of Biology and CeBiTec, Bielefeld University, Universitätsstr. 25, 33615, Bielefeld, Germany.ORCID http://orcid.org/0000-0001-6697-7971
Lilli Sophie KaimannGenetics of Prokaryotes, Faculty of Biology and CeBiTec, Bielefeld University, Universitätsstr. 25, 33615, Bielefeld, Germany.
Kai H SchülkeOrganic Chemistry and Biocatalysis, Faculty of Chemistry and CeBiTec, Bielefeld University, Universitätsstr. 25, 33615, Bielefeld, Germany.ORCID http://orcid.org/0000-0003-3486-5400
Stephan C HammerOrganic Chemistry and Biocatalysis, Faculty of Chemistry and CeBiTec, Bielefeld University, Universitätsstr. 25, 33615, Bielefeld, Germany.ORCID http://orcid.org/0000-0002-3620-9362
Volker F WendischGenetics of Prokaryotes, Faculty of Biology and CeBiTec, Bielefeld University, Universitätsstr. 25, 33615, Bielefeld, Germany. volker.wendisch@uni-bielefeld.de.ORCID http://orcid.org/0000-0003-3473-0012

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundN-Acetyltyramine is increasingly recognized for its diverse pharmaceutically relevant properties. In particular, it exhibits antimicrobial activity against multi-drug resistant pathogens, which pose a considerable health challenge. Therefore, the demand for a sustainable and efficient N-acetyltyramine production arises.

resultsHere, we engineered Corynebacterium glutamicum for de novo production of N-acetyltyramine. Heterologous overexpression of different bacterial and insect acetyltransferase genes in a tyramine overproducing strain identified the arylalkylamine N-acetyltransferase from Bombyx mori as the most promising enzyme, resulting in an N-acetyltyramine titer of 5.5 ± 0.3 mM. Design of Experiment-based optimization of the culture medium revealed urea and L-phenylalanine as media components significantly affecting N-acetyltyramine production. Combining media optimization with genetic engineering to balance the expression strength of the genes encoding the L-tyrosine decarboxylase from Levilactobacillus brevis and the arylalkylamine N-acetyltransferase from B. mori increased de novo N-acetyltyramine production to 13.8 ± 0.1 mM (2.5 ± 0.1 g/L). The optimized medium composition was also transferable to the production of other L-tyrosine derivatives, tyramine and tyrosol, increasing their titers by 24% and 44%, respectively. In addition, supplementing the established N-acetyltyramine producing strain with propionate as a second carbon source enabled the production of N-propionyltyramine. To the best of our knowledge, this represents the first report describing biotechnological production of N-propionyltyramine.

conclusionIn this study, de novo N-acetyltyramine production was established and substantially increased through the combined implementation of metabolic engineering and media optimization strategies. The successful transfer of the optimized medium to enhance the production of additional L-tyrosine derivatives underscores the potential of integrating genetic engineering with culture media refinement to improve biotechnological processes.

Indexed as

Arylalkylamine N-acetyltransferaseCorynebacterium glutamicumDesign of experimentsN-AcetyltyramineN-Propionyltyramine

Identifiers

PMID42316222
PMCPMC13281258

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.